Creating next generation medicines: research collaboration announced with Roche

Research collaboration with the Swiss-based healthcare company Roche

A new research collaboration with the Swiss-based healthcare company Roche (F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.) was announced in November 2016. The collaboration aims to develop next generation treatments for autoimmune diseases, focused on proteins targeting novel molecular pathways. It arose from work performed by Marcel Nold and Claudia Nold from the Hudson Institute and Monash University’s Department of Paediatrics together with James Whisstock and Andrew Ellisdon from the Monash Biomedicine Discovery Institute. All four scientists are part of the Australian Research Council Centre of Excellence in Advanced Molecular Imaging which is headquartered at Monash.

The partnership will enable the multi-disciplinary research team and Roche to work together to advance and translate existing and new intellectual property into novel treatments. The project will combine skills in clinical immunology, cytokine research and drug development approaches and will take advantage of new structural biology technology available at Monash including nanocrystallisation robotics and the FEI Titan KRIOS, a multi-million dollar electron microscope used to guide the design of new biologic drugs.

Roche has the option to exclusively licence the intellectual property for development and commercialisation of proteins targeting novel molecular pathways in return for significant development and commercial milestones payments and royalties on product sales.